DRD2 and type 2 diabetes mellitus: In such pathophysiological states of T2D, circadian-timed administration of the sympatholytic dopamine D2 receptor agonist, bromocriptine-QR, to reinstate the natural circadian peak of CNS dopaminergic activity (and reduce elevated SNS tone) leads to improvement of glucose and lipid dysmetabolism and attenuation of cardiometabolic risk.